Skip to main content
NASDAQ:MIRM

Mirum Pharmaceuticals Competitors

$17.49
-0.25 (-1.41 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.14
$18.26
50-Day Range
$17.70
$20.60
52-Week Range
$14.94
$27.43
Volume118,300 shs
Average Volume126,062 shs
Market Capitalization$532.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2.44

Competitors

Mirum Pharmaceuticals (NASDAQ:MIRM) Vs. IGMS, LGND, RCUS, RVNC, DRNA, and FGEN

Should you be buying MIRM stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Mirum Pharmaceuticals, including IGM Biosciences (IGMS), Ligand Pharmaceuticals (LGND), Arcus Biosciences (RCUS), Revance Therapeutics (RVNC), Dicerna Pharmaceuticals (DRNA), and FibroGen (FGEN).

Mirum Pharmaceuticals (NASDAQ:MIRM) and IGM Biosciences (NASDAQ:IGMS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Institutional and Insider Ownership

72.9% of Mirum Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.6% of IGM Biosciences shares are owned by institutional investors. 45.5% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 79.3% of IGM Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Mirum Pharmaceuticals and IGM Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirum PharmaceuticalsN/AN/A$-52,550,000.00($4.58)-3.82
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-13.73

IGM Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mirum Pharmaceuticals and IGM Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirum PharmaceuticalsN/A-61.90%-54.46%
IGM BiosciencesN/A-33.30%-30.28%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Mirum Pharmaceuticals and IGM Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirum Pharmaceuticals00613.14
IGM Biosciences01602.86

Mirum Pharmaceuticals presently has a consensus target price of $40.1667, indicating a potential upside of 129.66%. IGM Biosciences has a consensus target price of $98.8750, indicating a potential upside of 50.04%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Mirum Pharmaceuticals is more favorable than IGM Biosciences.

Volatility & Risk

Mirum Pharmaceuticals has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of -1.12, indicating that its share price is 212% less volatile than the S&P 500.

Summary

Mirum Pharmaceuticals beats IGM Biosciences on 7 of the 11 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

72.9% of Mirum Pharmaceuticals shares are held by institutional investors. 10.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 45.5% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Ligand Pharmaceuticals and Mirum Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$120.28 million17.35$629.30 million$2.1159.41
Mirum PharmaceuticalsN/AN/A$-52,550,000.00($4.58)-3.82

Ligand Pharmaceuticals has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ligand Pharmaceuticals and Mirum Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ligand Pharmaceuticals-11.23%5.90%3.22%
Mirum PharmaceuticalsN/A-61.90%-54.46%

Analyst Recommendations

This is a summary of recent recommendations for Ligand Pharmaceuticals and Mirum Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ligand Pharmaceuticals01602.86
Mirum Pharmaceuticals00613.14

Ligand Pharmaceuticals currently has a consensus price target of $214.00, indicating a potential upside of 70.72%. Mirum Pharmaceuticals has a consensus price target of $40.1667, indicating a potential upside of 129.66%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Volatility & Risk

Ligand Pharmaceuticals has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500.

Summary

Mirum Pharmaceuticals beats Ligand Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Arcus Biosciences (NYSE:RCUS) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Profitability

This table compares Arcus Biosciences and Mirum Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcus Biosciences-112.63%-27.43%-20.96%
Mirum PharmaceuticalsN/A-61.90%-54.46%

Institutional and Insider Ownership

60.6% of Arcus Biosciences shares are held by institutional investors. Comparatively, 72.9% of Mirum Pharmaceuticals shares are held by institutional investors. 19.7% of Arcus Biosciences shares are held by insiders. Comparatively, 45.5% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Arcus Biosciences and Mirum Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcus Biosciences00903.00
Mirum Pharmaceuticals00613.14

Arcus Biosciences currently has a consensus price target of $51.50, indicating a potential upside of 76.67%. Mirum Pharmaceuticals has a consensus price target of $40.1667, indicating a potential upside of 129.66%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Arcus Biosciences.

Volatility & Risk

Arcus Biosciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500.

Valuation & Earnings

This table compares Arcus Biosciences and Mirum Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$15 million137.97$-84,710,000.00($1.93)-15.10
Mirum PharmaceuticalsN/AN/A$-52,550,000.00($4.58)-3.82

Mirum Pharmaceuticals has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Mirum Pharmaceuticals beats Arcus Biosciences on 9 of the 14 factors compared between the two stocks.

Mirum Pharmaceuticals (NASDAQ:MIRM) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Mirum Pharmaceuticals and Revance Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirum PharmaceuticalsN/A-61.90%-54.46%
Revance Therapeutics-5,818.87%-85.72%-44.85%

Institutional and Insider Ownership

72.9% of Mirum Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are owned by institutional investors. 45.5% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Revance Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Mirum Pharmaceuticals and Revance Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirum Pharmaceuticals00613.14
Revance Therapeutics00403.00

Mirum Pharmaceuticals currently has a consensus target price of $40.1667, indicating a potential upside of 129.66%. Revance Therapeutics has a consensus target price of $38.50, indicating a potential upside of 37.84%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Revance Therapeutics.

Risk & Volatility

Mirum Pharmaceuticals has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mirum Pharmaceuticals and Revance Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirum PharmaceuticalsN/AN/A$-52,550,000.00($4.58)-3.82
Revance Therapeutics$410,000.004,862.75$-159,430,000.00($3.67)-7.61

Mirum Pharmaceuticals has higher earnings, but lower revenue than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Mirum Pharmaceuticals beats Revance Therapeutics on 10 of the 14 factors compared between the two stocks.

Mirum Pharmaceuticals (NASDAQ:MIRM) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Mirum Pharmaceuticals and Dicerna Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirum PharmaceuticalsN/A-61.90%-54.46%
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%

Institutional and Insider Ownership

72.9% of Mirum Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. 45.5% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Mirum Pharmaceuticals and Dicerna Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirum Pharmaceuticals00613.14
Dicerna Pharmaceuticals00503.00

Mirum Pharmaceuticals currently has a consensus target price of $40.1667, indicating a potential upside of 129.66%. Dicerna Pharmaceuticals has a consensus target price of $42.2857, indicating a potential upside of 64.41%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Dicerna Pharmaceuticals.

Risk & Volatility

Mirum Pharmaceuticals has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mirum Pharmaceuticals and Dicerna Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirum PharmaceuticalsN/AN/A$-52,550,000.00($4.58)-3.82
Dicerna Pharmaceuticals$23.90 million82.76$-120,460,000.00($1.76)-14.61

Mirum Pharmaceuticals has higher earnings, but lower revenue than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Mirum Pharmaceuticals beats Dicerna Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Mirum Pharmaceuticals (NASDAQ:MIRM) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Mirum Pharmaceuticals and FibroGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirum PharmaceuticalsN/A-61.90%-54.46%
FibroGen-191.78%-48.19%-27.72%

Institutional and Insider Ownership

72.9% of Mirum Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.1% of FibroGen shares are owned by institutional investors. 45.5% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 3.4% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Mirum Pharmaceuticals and FibroGen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirum Pharmaceuticals00613.14
FibroGen14202.14

Mirum Pharmaceuticals currently has a consensus target price of $40.1667, indicating a potential upside of 129.66%. FibroGen has a consensus target price of $47.00, indicating a potential upside of 122.43%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than FibroGen.

Risk & Volatility

Mirum Pharmaceuticals has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mirum Pharmaceuticals and FibroGen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirum PharmaceuticalsN/AN/A$-52,550,000.00($4.58)-3.82
FibroGen$256.58 million7.58$-76,970,000.00($0.89)-23.74

Mirum Pharmaceuticals has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Mirum Pharmaceuticals beats FibroGen on 9 of the 14 factors compared between the two stocks.


Mirum Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$65.90-0.3%$2.11 billionN/A-28.04Earnings Announcement
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$125.35-4.1%$2.09 billion$120.28 million-126.62Analyst Report
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.7$29.15-1.4%$2.07 billion$15 million-15.26Analyst Downgrade
Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.93-2.1%$1.99 billion$410,000.00-6.07Earnings Announcement
Analyst Report
News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$25.72-4.4%$1.98 billion$23.90 million-15.98Earnings Announcement
Analyst Revision
FibroGen logo
FGEN
FibroGen
1.8$21.13-4.6%$1.95 billion$256.58 million-8.10Earnings Announcement
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.98-6.2%$1.92 billion$34.51 million-17.93Analyst Report
Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$33.01-1.6%$1.91 billion$25 million-6.60Analyst Report
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$20.67-4.4%$1.88 billionN/A-7.36Earnings Announcement
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$11.16-1.5%$1.80 billion$428.41 million16.17Earnings Announcement
Morphic logo
MORF
Morphic
1.5$49.25-2.7%$1.78 billion$16.98 million-31.57Analyst Report
Gap Down
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.32-2.3%$1.74 billion$26.87 million-12.73Earnings Announcement
Analyst Report
MacroGenics logo
MGNX
MacroGenics
1.4$28.94-5.6%$1.74 billion$64.19 million-9.25
Generation Bio logo
GBIO
Generation Bio
1.8$30.60-0.8%$1.73 billionN/A0.00Earnings Announcement
News Coverage
Amarin logo
AMRN
Amarin
1.6$4.35-6.0%$1.71 billion$429.76 million-86.98Analyst Downgrade
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$24.75-1.5%$1.64 billionN/A-15.18Earnings Announcement
Analyst Downgrade
Analyst Revision
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$19.74-4.8%$1.63 billionN/A0.00
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.41-6.1%$1.60 billion$145.97 million-7.05Earnings Announcement
Analyst Upgrade
Analyst Revision
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
2.0$5.32-2.3%$1.60 billion$1.63 billion12.98Earnings Announcement
Analyst Upgrade
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.6$44.30-7.0%$1.57 billionN/A0.00Earnings Announcement
Insider Selling
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.9$29.43-0.2%$1.56 billion$392.76 million12.21Analyst Revision
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.13-4.3%$1.54 billionN/A0.00Earnings Announcement
Cassava Sciences logo
SAVA
Cassava Sciences
1.1$37.49-4.6%$1.50 billionN/A-156.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$21.69-0.4%$1.49 billion$2.34 million-9.19Analyst Report
Gap Down
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$42.07-6.9%$1.48 billionN/A0.00Gap Down
uniQure logo
QURE
uniQure
1.7$31.97-2.6%$1.47 billion$7.28 million-8.48Earnings Announcement
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$11.29-0.5%$1.45 billion$320,000.00-7.68
Kronos Bio logo
KRON
Kronos Bio
1.7$25.43-3.7%$1.43 billionN/A0.00Earnings Announcement
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.00-1.7%$1.40 billionN/A0.00Analyst Report
Gap Up
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.26-8.7%$1.37 billionN/A-2.95
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$31.30-4.1%$1.36 billionN/A-10.54Earnings Announcement
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.5$35.81-0.9%$1.31 billionN/A-19.89Earnings Announcement
Analyst Upgrade
Analyst Revision
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.56-4.7%$1.31 billion$82.27 million-16.00Earnings Announcement
Analyst Report
Gap Down
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$29.29-0.8%$1.29 billion$230,000.00-13.62Analyst Revision
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$29.60-2.1%$1.29 billion$6.20 million-12.98News Coverage
Gap Down
Zymeworks logo
ZYME
Zymeworks
1.6$27.58-2.9%$1.27 billion$29.54 million-7.32Analyst Revision
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.6$28.33-1.1%$1.27 billionN/A0.00Insider Selling
High Trading Volume
News Coverage
Endo International logo
ENDP
Endo International
1.5$5.43-5.0%$1.27 billion$2.91 billion-7.99Earnings Announcement
Analyst Revision
Innoviva logo
INVA
Innoviva
1.1$12.37-1.9%$1.25 billion$261.02 million6.31
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$18.87-1.7%$1.23 billion$73.41 million-3.99Analyst Report
Analyst Revision
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.59-2.3%$1.19 billion$59.70 million-195.90
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$32.21-2.2%$1.19 billionN/A0.00
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.38-2.4%$1.17 billion$4.23 million-8.59Analyst Revision
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$19.39-2.3%$1.17 billion$175.34 million-11.41Earnings Announcement
Shattuck Labs logo
STTK
Shattuck Labs
1.5$27.75-2.7%$1.16 billionN/A0.00Earnings Announcement
Insider Selling
High Trading Volume
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$21.77-2.8%$1.13 billion$4.23 million-16.13Earnings Announcement
Keros Therapeutics logo
KROS
Keros Therapeutics
1.5$48.54-4.3%$1.13 billionN/A0.00Earnings Announcement
Analyst Downgrade
Analyst Revision
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$31.15-5.5%$1.12 billion$57.05 million0.00Earnings Announcement
Gap Down
Omeros logo
OMER
Omeros
1.4$17.85-3.2%$1.11 billion$111.81 million-7.50Earnings Announcement
Analyst Downgrade
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.